. . . . . . . . . . . . . . . . "a(SCHEM:Dinoprostone) -> bp(GOBP:\"cell proliferation\")" . "composite(a(CHEBI:erlotinib),a(SCHEM:SC58236)) -| (a(SCHEM:Dinoprostone) -> bp(GOBP:\"cell proliferation\"))" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "20131211" . "To determine the capacity of EGFR inhibition to block PGE2-dependent cell proliferation, cells were pretreated with Erlotinib or PD153035 prior to PGE2 stimulation. We observed a significant increase of NSCLC cell proliferation in response to PGE2 treatment that was resistant to EGFR inhibition (Fig. 6). Treatment with EGFR inhibitors or sc58236 alone had only a modest effect on cell proliferation. However, treatment with the combination of both drugs significantly decreased proliferation of NSCLC cells compared with either drug alone or nontreated control cells." . . "Selventa" . . . . "2014-07-03T14:32:47.654+02:00"^^ . . .